Campbell & CO Investment Adviser LLC Makes New $309,000 Investment in Ultragenyx Pharmaceutical Inc. $RARE

Campbell & CO Investment Adviser LLC bought a new position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) in the second quarter, according to its most recent disclosure with the SEC. The firm bought 8,486 shares of the biopharmaceutical company’s stock, valued at approximately $309,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Oak Ridge Investments LLC grew its holdings in shares of Ultragenyx Pharmaceutical by 2.3% in the first quarter. Oak Ridge Investments LLC now owns 17,757 shares of the biopharmaceutical company’s stock valued at $643,000 after purchasing an additional 395 shares during the period. Teacher Retirement System of Texas grew its stake in shares of Ultragenyx Pharmaceutical by 1.8% in the 2nd quarter. Teacher Retirement System of Texas now owns 22,773 shares of the biopharmaceutical company’s stock valued at $828,000 after buying an additional 404 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. grew its stake in shares of Ultragenyx Pharmaceutical by 7.0% in the 2nd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 6,783 shares of the biopharmaceutical company’s stock valued at $247,000 after buying an additional 441 shares during the period. Public Employees Retirement System of Ohio increased its holdings in shares of Ultragenyx Pharmaceutical by 2.0% during the 2nd quarter. Public Employees Retirement System of Ohio now owns 27,885 shares of the biopharmaceutical company’s stock worth $1,014,000 after buying an additional 543 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in shares of Ultragenyx Pharmaceutical by 18.0% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,652 shares of the biopharmaceutical company’s stock valued at $133,000 after buying an additional 557 shares during the period. Institutional investors and hedge funds own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Price Performance

Shares of Ultragenyx Pharmaceutical stock opened at $32.54 on Tuesday. The stock has a market capitalization of $3.14 billion, a price-to-earnings ratio of -5.88 and a beta of 0.30. The business has a 50-day moving average of $31.65 and a 200 day moving average of $32.57. Ultragenyx Pharmaceutical Inc. has a 12 month low of $25.81 and a 12 month high of $50.00.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported ($1.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.23) by ($0.58). The business had revenue of $159.93 million for the quarter, compared to analyst estimates of $167.42 million. Ultragenyx Pharmaceutical had a negative return on equity of 237.48% and a negative net margin of 87.34%.The firm’s revenue for the quarter was up 14.6% compared to the same quarter last year. During the same period in the prior year, the company posted ($1.40) EPS. Ultragenyx Pharmaceutical has set its FY 2025 guidance at EPS. Equities research analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the company. Cantor Fitzgerald reissued an “overweight” rating and set a $105.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Friday, September 5th. Weiss Ratings reissued a “sell (e+)” rating on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, October 8th. Wells Fargo & Company began coverage on shares of Ultragenyx Pharmaceutical in a report on Monday, October 20th. They issued an “overweight” rating and a $65.00 price objective on the stock. TD Cowen decreased their target price on shares of Ultragenyx Pharmaceutical from $86.00 to $75.00 and set a “buy” rating on the stock in a research report on Wednesday, November 5th. Finally, Canaccord Genuity Group dropped their price target on shares of Ultragenyx Pharmaceutical from $136.00 to $128.00 and set a “buy” rating for the company in a research report on Friday, August 8th. Eleven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $82.75.

Insider Activity at Ultragenyx Pharmaceutical

In related news, CFO Howard Horn sold 7,942 shares of Ultragenyx Pharmaceutical stock in a transaction on Monday, October 13th. The stock was sold at an average price of $31.51, for a total value of $250,252.42. Following the completion of the transaction, the chief financial officer directly owned 98,227 shares in the company, valued at approximately $3,095,132.77. This trade represents a 7.48% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Karah Herdman Parschauer sold 2,450 shares of the business’s stock in a transaction on Friday, September 12th. The stock was sold at an average price of $31.17, for a total value of $76,366.50. Following the transaction, the executive vice president directly owned 73,271 shares of the company’s stock, valued at $2,283,857.07. The trade was a 3.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 10,456 shares of company stock valued at $328,486 in the last three months. 5.50% of the stock is currently owned by corporate insiders.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.